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Abstract 
Background: It has been estimated that approximately 15% of people who are incarcerated in the US have histories 
of opioid use disorder. Relapse to opioid use after release from prison poses a serious risk of HIV infection. Prison-
initiated buprenorphine may help to reduce HIV infection given the association between opioid use and HIV-risk 
behaviors.
Methods: The present study is a secondary analysis of longitudinal data gathered from a randomized controlled 
trial of buprenorphine-naloxone for people who were incarcerated (N = 211) between 2008 and 2012. It compares 
the impact of assignment to initiate buprenorphine in prison (N = 106 randomized, N = 104 analyzed) versus in the 
community (N = 107 randomized, N = 107 analyzed) and whether or not participants entered community treatment 
on the frequency of HIV-risk behaviors in the 12 months following release from prison. Data were analyzed hierarchi-
cally and for each outcome variable, a multilevel, over-dispersed Poisson model was fit to the data. Outcome variables 
were the number of times the following behaviors occurred in the last 30 days: (1) having sex without a condom (2) 
injecting drugs (3) using unsterilized needles, and (4) sharing injection paraphernalia.
Results: Participants assigned to begin buprenorphine in the community experienced a greater decrease in injection 
drug use over time compared to participants assigned to begin buprenorphine in prison. There were no significant 
associations between treatment assignment or community treatment entry and instances of having sex without a 
condom, sharing injection paraphernalia, or using unsterilized needles.
Conclusions: Overall, the present study did not find support for the initiation of buprenorphine in prison (as 
opposed to the community) as a means to reduce incidences of HIV-risk behaviors. Avenues for future research in the 
nexus of HIV-risk reduction, criminal justice, and pharmacotherapy are discussed.
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Background
The United States (US) leads the world in both the num-
ber of incarcerated persons and rate of incarceration. Fig-
ures from 2016 estimate the total number of incarcerated 
persons in the US at 1.5 million and a rate of incarcera-
tion in jails or prisons of 670 per 100,000 [1]. Compared 
to the general population, incarcerated persons have 
a disproportionally higher rate of opioid use disorders 
(OUDs) [2–4]; 13.1% and 9.2% of people incarcerated in 
state and federal prisoners respectively reported using 
heroin or other opiates regularly in the community 
before their incarceration [5]. Given that the vast major-
ity of incarcerated persons will be released from prison 
at some point and that 626,024 individuals were released 
from state and federal prisons in 2016 [6], there is a con-
siderable need to deliver effective treatment to this popu-
lation in order to reduce relapse to drug use upon release.
A return to illicit psychoactive substance use upon 
community re-entry poses significant risks to health and 
public safety [7]. Individuals recently released from jail 
or prison are at increased risk for overdose death within 
their first month in the community [8–17] and a return 
to opioid use is associated with criminal activity [7, 18, 
19] and re-incarceration [18, 20, 21]. Relapse to drug use 
is also a significant public health concern as it heightens 
the risk for HIV and hepatitis B and C infections [2, 4, 7].
The Centers for Disease Control and Prevention 
(CDC) estimated that in the US there are approximately 
1.1  million people who were HIV positive in 2015 [22]. 
Of that group, one in seven individuals were unaware 
of their HIV status [22]. In 2015, HIV was the 9th lead-
ing cause of death for those 25 to 44  years of age [22]. 
As with OUDs, HIV infection is overrepresented in the 
criminal justice population with estimated rates rang-
ing between three and five times greater than that of the 
general population [23–25]. The higher incidence of HIV 
infection amongst criminal justice populations is at least 
partially attributable to their increased rates of substance 
use disorders. Substance use exacerbates the risk of HIV 
through the practice of injection drug use, the sharing 
of needles and injection paraphernalia (cookers, cotton, 
and rinse water), and its association with risky sex, sex 
with multiple partners, and transactional sex/sex work 
[26–30]. For example, a longitudinal study by MacGowan 
and colleagues found that among men recently released 
from prison, the only factor independently associated 
with risky sex was the use of alcohol or illicit substances 
before sex [31]. Substantial research evidence indicates 
that men and women with OUDs differ in terms of their 
health and substance use treatment needs and their risk 
of HIV infection. Among individuals with OUDs, women 
are more likely than men to suffer from serious medi-
cal conditions [32–34], mental health problems [33, 35], 
unemployment [35, 36], the stress of having responsibil-
ity for child care [37], and the burden of having a spouse 
or partner with addiction problems [33, 34]. Moreover, 
an analysis by Binswanger and colleagues [38] of HIV risk 
behaviors for both men and women post-release found 
that a higher proportion of women than men engaged 
in several risk behaviors including unprotected sex and 
sex with multiple partners. In addition, they found that 
women were more prone than men to exchange sex for 
drugs and/or money.
While the practice of mandatory or opt-out HIV test-
ing has become more commonplace in state and federal 
prisons, [25] there is still a need for HIV risk-reduction 
interventions for criminal justice involved individuals 
[26]. One promising avenue for improving public health 
outcomes, is the use of opioid agonist therapy (OAT) for 
the treatment of OUD. Reviews of studies involving OAT 
and HIV-risk behaviors have shown that both methadone 
and buprenorphine may help to reduce injection drug 
use, needle sharing, and risky sexual behaviors [26, 39]. 
However, these studies often focus on community sam-
ples and there is limited research on the effects of prison-
initiated OAT on HIV-risk behaviors [39, 40] presenting 
an opportunity for study.
For the treatment of OUDs, the three pharmacothera-
pies approved by the U.S. Food and Drug Administration 
(methadone, buprenorphine, and naltrexone) represent 
the highest standard of care, but are rarely implemented 
within the criminal justice system [41–43]. Given their 
demonstrated efficacy in community settings [44, 45], 
implementation of pharmacotherapies prior to release 
may help to prevent illicit opioid use in prison and 
relapse upon release for individuals who have maintained 
opioid abstinence while incarcerated. In turn, a reduc-
tion in the rates of relapse to opioid use upon release can 
help to reduce the incidence of HIV infections through 
a reduction in injection drug use and risky sex behav-
iors. A review of studies of pre-release opioid agonist 
therapies (OAT) found that pre-release OAT in prison is 
associated with significantly increased treatment uptake 
after release and treatment retention, with differences 
observed as far as 12 months post-release [46]. Given the 
importance of substance use treatment retention for pos-
itive treatment outcomes [47, 48], this finding supports 
the use of pre-release OAT for reducing relapse to opioid 
use and its associated harms, including the risk of HIV 
infection.
Our research group has previously reported on find-
ings from a randomized clinical trial that compared 
post-release outcomes of incarcerated persons with pre-
incarceration histories of opioid dependence (defined by 
DSM-IV) who were randomly assigned to begin sublin-
gual buprenorphine/naloxone prior to versus post-release 
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from prison [49, 50]. The study found that participants 
who were randomly assigned to initiate buprenorphine 
in prison were significantly more likely to enter and to 
remain in buprenorphine treatment in the community 
compared to participants who were assigned to begin 
buprenorphine treatment after release [50]. However, 
despite greater community treatment exposure, there 
were no significant differences between treatment condi-
tions in heroin and cocaine use at the 12-month follow-
up [50].
The present study
The aim of the present study is to examine the impact of 
initiating buprenorphine prior to versus post-release on 
relative incidences of four key HIV risk behaviors: (1) 
sex without a condom (2) injection drug use (3) using 
unsterilized needles, and (4) sharing injection parapher-
nalia. Here we present findings from a secondary analy-
sis of data from the above-mentioned clinical trial. We 
hypothesized that because of the potential advantages 
of initiating buprenorphine treatment in prison (higher 
rates of treatment entry and treatment retention) that 
there would be greater levels of improvement (greater 
decreases) in the number of self-reported incidences of 
each of the four HIV risk behaviors over time when con-
trolling for gender and community treatment entry. The 
parent study found that the study condition assigned 
to initiate buprenorphine in prison compared to after 
release was associated with significantly higher rates of 
community treatment entry and community treatment 
exposure. While greater participation in treatment post-
release did not produce significant differences in heroin 
or cocaine use, it may have impacted other aspects of 
substance use that are related to increased HIV risk (i.e. 
using unsterilized needles, exchanging sex for drugs) 




Participants in the parent study were 211 adults incar-
cerated in prison with a history of DSM-IV defined 
opioid dependence in the year prior to their index incar-
ceration. They were recruited between 2008 and 2012 
within 3 to 9  months prior to their release. All partici-
pants regardless of condition assignment were offered 
12 weekly group-based substance use counseling ses-
sions in prison. They were randomly assigned to initiate 
sublingual buprenorphine/naloxone, hereafter termed 
buprenorphine, either in prison (N = 106 randomized, 
N = 104 analyzed, N = 2 missing all data) or post-release 
(N = 107 randomized, N = 107 analyzed). Additionally, 
they were randomly assigned to receive buprenorphine 
treatment post-release in either an opioid treatment pro-
gram (OTP) or in a community health center (CHC). In 
partnership with the participating community treatment 
facilities, participants in the study were granted guaran-
teed admission if they reported to their assigned facility 
within 10  days of release. However, because the parent 
study found no differences between assignment follow-
ing release into the community to an OTP or a CHC, 
the present study focuses on the condition assignment 
to initiate buprenorphine either pre- or post-release 
from prison. Buprenorphine was started at low doses 
(1/0.25 mg buprenorphine/naloxone daily) and increased 
slowly (e.g., increase of 1/0.25 mg per week until reach-
ing 4/1  mg with subsequent increases by 2/0.5  mg per 
week to reach 8/2  mg) because most participants were 
not opioid tolerant at the time of study recruitment. This 
dosing schedule is much slower than would be used for 
opioid-tolerant patients in the community. Vocci et  al. 
[51] provide a detailed treatment of buprenorphine dose 
induction for non-opioid tolerant pre-release incarcer-
ated persons. Prior to release, exit interviews were held 
with participants where the importance of promptly 
reporting to their designated post-release treatment facil-
ity was emphasized. Participants were also given business 
cards containing information about the community-
based treatment program they were assigned to attend 
[52]. Eighty-two (38.9%) of participants entered com-
munity treatment within 10 days. A detailed description 
of the methods and outcomes of the parent study can 
be found elsewhere [49, 50, 52]. The parent study was 
approved by the Friends Research Institute’s Institutional 
Review Board, the Maryland Department of Public Safety 
and Correctional Services Research Committee, and the 
Federal Office for Human Research Protections. The 
ClinicalTrials.gov identifier is NCT 00574067.
Measures
Predictor variables
The predictor variables can be considered as either 
treatment or control variables. The treatment variable, 
the main variable of interest, was the assigned treat-
ment condition: buprenorphine initiated in prison 
versus buprenorphine initiated in the community. The 
control variables were participant community treat-
ment entry and gender. Participants were considered to 
have successfully entered community treatment if they 
reported to their assigned buprenorphine treatment 
program within 10 days of release. The control variables 
are included in the analyses so that the effect of treat-
ment condition can be ascertained above and beyond 
the effects of community treatment entry and partici-
pant gender.
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Outcome variables
As part of the study protocol, HIV-risk behaviors were 
reported at study entry (in prison) and at 1, 3, 6, and 
12 months post-release using the Texas Christian Univer-
sity HIV/AIDS Risk Assessment. This measure assesses 
HIV knowledge and sexual and injected-related risk 
behaviors during the preceding 30-day period. It has 
been used to assess the effectiveness of community out-
reach interventions on reducing AIDS risk [53] and to 
study the cognitive and psychosocial factors associated 
with HIV/AIDS risk behavior [54, 55]. Data were in the 
form of self-reported number of times engaging in each 
of the following behaviors in the last 30 days: (1) having 
sex without a condom (2) injecting drugs with a needle 
(3) using unsterilized (“dirty”) needles, and (4) sharing 
injection paraphernalia (“works”). In the case of self-
report data at study entry (during their index incarcera-
tion), participants recalled the number of times engaging 
in each behavior during their last 30  days in the com-
munity. Although follow-up measures were scheduled 
to be collected at specific, fixed times during the post-
release period, there were sometimes significant vari-
ations among participants in the actual dates at which 
assessments were completed or data for the outcomes of 
interest were missing at some follow-up intervals (rate of 
missing responses: 54%) due to the numerous challenges 
of gathering longitudinal data from criminal justice-
involved adults [56] including a lack of access to reliable 
transportation, unstable housing, requirements of com-
munity supervision, and re-arrest and re-incarceration 
[57, 58]. Therefore, the point in time when each assess-
ment was collected was scaled as the number of days 
since the baseline assessment. Because each of the four 
outcomes were evaluated by open-response items, partic-
ipants were free to enter any number for the incidences 
of each risk behavior that occurred in the past 30  days. 
In some cases, the self-reported incidences of HIV-risk 
behaviors appear to have been unrealistically large (e.g., 
injecting drugs 900 times in 30  days). To prevent these 
responses from distorting the results, a datum that 
exceeded 300 self-reported incidences of behavior in the 
last 30 days (indicating an average greater than 10 times 
per day) was treated as missing, an event that occurred 
in 12 instances. Given the flexibility of hierarchical lin-
ear models to deal with missing data, all other responses 
from participants with deleted data were retained. In 
total, over 2000 responses were collected during the 
12-month follow-up period meaning that deleted data 
represented less than 0.01% of all responses.
Statistical analysis
Data were evaluated longitudinally in order to account 
for the effects of time and to examine how the treatment 
and control variables were related to the rate of change 
in HIV-risk behaviors over time. In order to accom-
plish this goal, a hierarchical framework was adopted. 
Observations at separate time points (level-1 data) were 
considered nested within participants (level-2 data). 
A hierarchical framework is useful for the evaluation 
of repeated measures data because of its flexibility to 
accommodate unbalanced data structures where the data 
for some (or all) individuals is incomplete or when par-
ticipants are measured at different sets of time points 
[59]. In order to achieve the aim of the present study, 
a multilevel, over-dispersed Poisson model was fit to 
the data for each of the four outcomes: (1) sex without 
a condom (2) injection drug use (3) using unsterilized 
needles, and (4) sharing injection paraphernalia. To cor-
rect for multiple comparisons across these four outcome 
variables, a Bonferroni correction was performed and a 
reduced α of 0.0125 (0.05 ÷ 4) was used as the criterion 
for statistical significance (p values for all statistical tests 
are reported in Tables  3, 4, 5, 6). Each model consisted 
of two levels. The level-1 and level-2 model equations as 
well as the mixed model equation are detailed in Fig. 1. 
In the level-1 model the log count of the outcome meas-
ure was predicted by an intercept and the number of 
days since baseline assessments. In the level-2 model, 
the level-1 intercept was predicted by participant gen-
der (male = 0; female = 1). The coefficient (linear trend) 
of time was predicted by an intercept, participant gen-
der, treatment condition (buprenorphine initiated in the 
community = 0; buprenorphine initiated in prison = 1), 
community treatment entry (entered treatment within 
10  days of release from prison: no = 0; yes = 1) and the 
interaction effect between treatment condition and com-
munity treatment entry. The intercept for the coefficient 
of time is the change in log counts of the outcome vari-
able per day when all other predictors are equal to zero. 
This intercept determines the change in event rate ratio 
(ERR) for male participants assigned to begin buprenor-
phine in the community, but who failed to enter treat-
ment. The treatment condition by community treatment 
interaction term was deleted from the final model if it 
was not statistically significant. Hierarchical models were 
fit to the data using HLM for Windows Version 7.03.
Results
Participants
Participants in the present study were 211 adults incar-
cerated in prison who met the criteria for DSM-IV 
defined opioid dependence at the time of incarcera-
tion and had between 3 and 9 months remaining before 
their anticipated release. The sample was 70.1% male 
(randomized to begin buprenorphine in prison n = 72; 
randomized to begin buprenorphine in the community 
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n = 76) and 29.9% female (randomized to begin 
buprenorphine in prison n = 32; randomized to begin 
buprenorphine in the community n = 31). The majority 
of participants self-identified as Black (n = 148; 70.1%); 
the next largest group was Whites (n = 54; 25.6%) fol-
lowed by American Indians (n = 3; 1.4%), Hispanics 
(n = 2; 0.9%), Asians and Pacific Islanders (n = 2; 0.9%), 
and those participants who identified as belonging to 
some other racial group (n = 2; 0.9%). On average, par-
ticipants were 39.08 years of age (SD = 8.8). The average 
age of heroin use onset was 19.3 years of age (SD = 5.9) 
and the average age of participants when they were first 
incarcerated was 21.0 years old (SD = 7.5). Participants 
reported using heroin on 24.5 (SD = 10.1) of their last 
30 days in the community on average. The vast majority 
of participants had received prior substance use treat-
ment (n = 173; 81.9%) but only about one third (n = 67; 
31.8%) had received prior methadone treatment and an 
even smaller proportion reported having received prior 
buprenorphine treatment (n = 32; 15.2%). Although 
participants were guaranteed entry into a community 
treatment program if they began treatment within 
10 days of release (as part of the intervention) only 82 
(38.9%; randomized to begin buprenorphine in prison 
n = 48; randomized to begin buprenorphine in the com-
munity n = 34) entered community treatment within 
10 days of release. Table 1 summarizes the frequencies 
of predictor variables included in the statistical model 
by treatment condition.
Fig. 1 Equations for the multilevel, over-dispersed Poisson models fit to each of the four outcome measures
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HIV‑risk behaviors
The means and standard deviations of each outcome var-
iable at baseline (study entry) and 12-month follow-up 
are presented in Table 2. Values for both the full sample 
and each treatment condition are provided at the earliest 
and latest time points in the study for comparison. Means 
displayed in the table take into account all available data 
at the given measurement point.
Sex without a condom
Results for the multilevel Poisson model are summa-
rized in Table  3. There were no significant differences 
between genders in the frequency of having sex with-
out a condom at baseline assessments [event rate ratio 
(ERR) = 1.09, 95% confidence interval (95% CI) = (0.79, 
1.53)]. There was a significant effect of time such that 
for the reference group (male participants assigned to 
initiate buprenorphine in the community who failed to 
enter community treatment) the incidence of sex with-
out a condom decreased by 3.6% for every 30  days in 
the community [ERR = 0.99, 95% CI = (0.998, 0.999)]. 
There were no gender differences in the rate at which 
incidences of risky sex changed over time [ERR = 1.00, 
95% CI = (1.00, 1.00)]. Surprisingly, neither was 
there a significant effect of either treatment condi-
tion [ERR = 1.00, 95% CI = (1.00, 1.00)] on the rate of 
change of risky sex behaviors, nor was there a signifi-
cant relationship between entry into community treat-
ment [ERR = 1.00, 95% CI = (1.00, 1.00)] and the rate of 
change of risky sex behaviors.
Table 1 Frequencies of  predictor variables included 











 Male 148 (70.14%) 76 (71.03%) 72 (69.23%)
 Female 63 (29.86%) 31 (28.97%) 32 (30.77%)
Entered community treatment
 Yes 82 (38.86%) 34 (31.78%) 48 (46.15%)
 No 129 (61.14%) 73 (68.22%) 56 (53.85%)







Baseline 12 months Baseline 12 months Baseline 12 months
Sex without a condom 22.97 (34.69) 12.18 (14.02) 21.42 (27.66) 11.88 (13.04) 24.57 (40.80) 12.46 (14.99)
Injection drug use 35.97 (63.66) 14.94 (48.68) 35.92 (67.81) 9.54 (27.92) 36.01 (59.47) 20.53 (63.09)
Using unsterilized needles 9.93 (30.28) 5.96 (20.58) 8.75 (26.20) 8.38 (27.37) 10.92 (33.55) 3.87 (12.83)
Sharing injection paraphernalia 26.16 (55.28) 11.07 (31.04) 35.08 (67.73) 14.08 (30.61) 19.10 (42.43) 8.47 (32.24)
Table 3 Results of the multilevel Poisson model for sex without a condom in the last 30 days
N = 211. b denotes the unstandardized partial regression coefficient; SE denotes its standard error. ERR denotes the event rate ratio for a one unit increase in the given 
variable. t denotes the t statistic for the given parameter estimate and d.f. is its degrees of freedom. Participant gender; male = 0; female = 1. Treatment condition; 
buprenorphine initiated in the community = 0; buprenorphine initiated in prison = 1. Whether or not the participant entered community treatment within 10 days of 
release from prison; no = 0; yes = 1
Effect b SE ERR (95% CI) t d.f. p
For intercept π0
 Intercept β00 2.70 0.09 14.88 (12.47, 17.75) 30.18 190 < 0.001
 Gender β01 0.09 0.17 1.09 (0.79, 1.53) 0.54 190 0.59
For days slope π1
 Intercept β10 − 0.001 0.0003 0.99 (0.998, 0.999) − 4.23 592 < 0.001
 Condition β11 0.0007 0.0004 1.00 (1.00, 1.00) 1.90 592 0.059
 Gender β12 0.0001 0.0004 1.00 (1.00, 1.00) 0.35 592 0.73
 Community treatment 
entry β13
0.00002 0.0005 1.00 (1.00, 1.00) 0.04 592 0.97
 Condition * community 
treatment entry β14
− 0.001 0.0007 0.99 (0.997, 1.00) − 2.15 592 0.03
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Injection drug use
Results of the multilevel Poisson model are summarized 
in Table  4. There were no significant gender differences 
either in the frequency of injection drug use at base-
line [ERR = 1.72, 95% CI = (0.91, 3.26)] or in the rate of 
change over time [ERR = 1.00, 95% CI = (1.00, 1.00)]. 
There was a significant effect of time such that for the 
reference group (male participants assigned to initiate 
buprenorphine in the community who failed to enter 
community treatment) the incidence of injection drug 
use decreased by 6.7% for every 30 days in the commu-
nity [ERR = 0.997, 95% CI = (0.997, 0.998)]. There was 
a significant effect of treatment condition on the rate 
of change in injection drug use over time [ERR = 1.002, 
95% CI = (1.001, 1.003)]. Surprisingly, the group that 
was assigned to begin buprenorphine in the community 
was found to have a greater decline in injection drug use 
such that per 30  days since study entry their frequency 
of injection drug use was 4.7% less than that of the con-
dition assigned to begin buprenorphine in prison. Lastly, 
there was no significant effect of community treatment 
entry [ERR = 0.999, 95% CI = (0.998, 1.00)] on incidences 
of injection drug use.
Using unsterilized needles
Results of the multilevel Poisson model are summarized 
in Table  5. There were no significant gender differences 
either in the frequency of using unsterilized needles 
at baseline [ERR = 1.74, 95% CI = (0.57, 5.27)] or in the 
rate of change over time [ERR = 1.00, 95% CI = (1.00, 
Table 4 Results of the multilevel Poisson model for injection drug use in the last 30 days
N = 211. b denotes the unstandardized partial regression coefficient; SE denotes its standard error. ERR denotes the event rate ratio for a one unit increase in the given 
variable. t denotes the t statistic for the given parameter estimate and d.f. is its degrees of freedom. Participant gender; male = 0; female = 1. Treatment condition; 
buprenorphine initiated in the community = 0; buprenorphine initiated in prison = 1. Whether or not the participant entered community treatment within 10 days of 
release from prison; no = 0; yes = 1
Effect b SE ERR (95% CI) t d.f. p
For intercept π0
 Intercept β00 2.07 0.18 7.92 (5.57, 11.28) 11.22 200 < 0.001
 Gender β01 0.55 0.32 1.72 (0.91, 3.26 1.69 200 0.09
For days slope π1
 Intercept β10 − 0.002 0.0004 0.997 (0.997, 0.998 − 6.26 744 < 0.001
 Condition β11 0.002 0.0005 1.002 (1.001, 1.003) 3.42 744 < 0.001
 Gender β12 − 0.0003 0.0005 1.00 (1.00, 1.00) − 0.56 744 0.58
 Community treatment 
entry β13
− 0.001 0.0006 0.999 (0.998, 1.00) − 2.37 744 0.02
 Condition * community 
treatment entry β14
– – – – – –
Table 5 Results of the multilevel Poisson model for using unsterilized needles in the last 30 days
N = 211. b denotes the unstandardized partial regression coefficient; SE denotes its standard error. ERR denotes the Event Rate Ratio for a one unit increase in 
the given variable. t denotes the t statistic for the given parameter estimate and d.f. is its degrees of freedom. Participant gender; male = 0; female = 1. Treatment 
condition; buprenorphine initiated in the community = 0; buprenorphine initiated in prison = 1. Whether or not the participant entered community treatment within 
10 days of release from prison; no = 0; yes = 1
Effect b SE ERR (95% CI) t d.f. p
For intercept π0
 Intercept β00 1.15 0.38 3.16 (1.50, 6.65) 3.02 94 0.003
 Gender β01 0.55 0.56 1.74 (0.57, 5.27) 0.99 94 0.33
For days slope π1
 Intercept β10 − 0.002 0.002 1.00 (1.00, 1.00) − 1.20 120 0.23
 Condition β11 − 0.0003 0.002 1.00 (1.00, 1.00) − 0.15 120 0.88
 Gender β12 − 0.0002 0.002 1.00 (1.00, 1.00) − 0.11 120 0.91
 Community treatment 
entry β13
− 0.01 0.006 1.00 (0.98, 1.00) − 1.58 120 0.12
 Condition * community 
treatment entry β14
– – – – – –
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1.00)]. Nor was there a main effect of time on the inci-
dence of using unsterilized needles [ERR = 1.00, 95% 
CI = (1.00, 1.00)]. There were also no significant effects of 
either treatment condition [ERR = 1.00, 95% CI = (1.00, 
1.00] or entering community treatment [ERR = 1.00, 
95% CI = (0.98, 1.00)] on the rate of change over time in 
instances of using unsterilized needles.
Sharing injection paraphernalia
Results of the multilevel Poisson model are summarized 
in Table  6. There were no significant gender differences 
either in the frequency of sharing injection parapherna-
lia at baseline [ERR = 1.38, 95% CI = (0.60, 3.19)] or in 
the rate of change over time [ERR = 1.00, 95% CI = (1.00, 
1.00)]. However, there was a significant effect of time 
such that for the reference group (male participants 
assigned to initiate buprenorphine in the community 
who failed to enter community treatment) the inci-
dence of sharing injection paraphernalia decreased by 
12.1% for every 30 days in the community [ERR = 0.996, 
95% CI = (0.993, 0.998)]. There were also no signifi-
cant effects for either treatment condition [ERR = 1.00, 
95% CI = (1.00, 1.00)] or entering community treatment 
[ERR = 1.00, 95% CI = (0.98, 1.00)] on the rate of change 
over time in instances of sharing injection paraphernalia.
Discussion
Overall, the present study did not find support for the 
initiation of buprenorphine in prison (as opposed to the 
community) as a means to reduce incidences of HIV-
risk behaviors. When examining injection drug use, 
the condition assigned to begin buprenorphine in the 
community reported fewer instances of injecting over 
time when compared to the group assigned to initiate 
buprenorphine in prison. This result is in contrast to the 
parent study [49] that did not find any differences in self-
reported heroin use, cocaine use, or treatment retention 
at 12  months. However, these results should be inter-
preted cautiously as only 40.3% of participants at baseline 
reported injecting drugs with a needle at least once in 
the last 30 days they were in the community suggesting 
they may prefer alternative routes of administration [60]. 
Therefore, changes in heroin or cocaine use over time 
would not necessarily mirror changes in injection drug 
use.
There were no significant predictors of decreasing 
incidences of sex without a condom, using unsterilized 
needles, or sharing injection paraphernalia in the pre-
sent study. However, it should be noted that in the case 
of using unsterilized needles, self-reported frequencies of 
this behavior were very low at baseline compared to the 
other HIV-risk behaviors (see Table 2) as some individu-
als use opioids exclusively intranasally.
The present findings contribute to the existing efforts 
to reduce HIV-risk behavior among prisoners treated 
with OAT. We are aware of only one other randomized 
trial of pre-release buprenorphine treatment in the US, 
which was conducted among short-sentenced inmates in 
New York City [61]. That study did not report HIV risk 
behavior [61]. In a review of the research on prison-based 
OAT and its effects on HIV-risk behaviors, Larney found 
some support for the use OAT in prison to reduce post-
release injection drug use and needle sharing [39]. How-
ever, the author noted a paucity of research in this area: 
only one of the five studies evaluated was a randomized 
controlled trial, and none of them took place in the US. 
Subsequent to the report by Larney, our group reported 
on post-release HIV-risk behavior from a randomized 
Table 6 Results of the multilevel Poisson model for sharing injection paraphernalia in the last 30 days
N = 211. b denotes the unstandardized partial regression coefficient; SE denotes its standard error. ERR denotes the event rate ratio for a one unit increase in the given 
variable. t denotes the t statistic for the given parameter estimate and d.f. is its degrees of freedom. Participant gender; male = 0; female = 1. Treatment condition; 
buprenorphine initiated in the community = 0; buprenorphine initiated in prison = 1. Whether or not the participant entered community treatment within 10 days of 
release from prison; no = 0; yes = 1
Effect b SE ERR (95% CI) t d.f. p
For intercept π0
 Intercept β00 2.51 0.28 12.30 (7.11, 21.30) 9.05 94 < 0.001
 Gender β01 0.32 0.42 1.38 (0.60, 3.19) 0.77 94 0.45
For days slope π1
 Intercept β10 − 0.004 0.001 0.996 (0.993, 0.998) − 3.4 118 < 0.001
 Condition β11 0.003 0.002 1.00 (1.00, 1.00) 1.92 118 0.06
 Gender β12 0.0003 0.002 1.00 (1.00, 1.00) 0.20 118 0.84
 Community treatment 
entry β13
− 0.007 0.004 0.99 (0.99, 1.00) − 1.72 118 0.09
 Condition * community 
treatment entry β14
– – – – – –
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trial comparing initiating methadone treatment during 
vs. post-release from prison compared to a counseling 
in prison and referral condition [40]. That study did not 
find not find significant differences between treatment 
conditions in the rate of change of HIV-sex or -drug 
risk behavior. However there were significant effects of 
treatment condition on drug-risk behaviors such that 
participants assigned to initiate methadone pre-release 
reported fewer incidences of drug-risk behaviors irre-
spective of time and there was a significant effect of time 
such that participants reported fewer incidences of drug-
risk behavior as the study progressed.
While there is limited research on the effects of prison-
initiated OAT on HIV-risk behaviors, there is evidence 
supporting the use of community-based OAT to reduce 
HIV-behaviors for both criminal-justice-involved persons 
[26] and the general population [62]. A review of HIV-
risk reduction strategies for criminal-justice-involved 
adults found that OAT significantly reduced injection 
drug use, but was less effective at reducing risky sexual 
behaviors [26]. These findings are echoed in reviews of 
studies involving general community samples [62]. Treat-
ment adherence appears to be a significant component 
for the success of OAT in reducing HIV-risk behaviors 
[62], consistent with the broader literature which reports 
that adherence to substance abuse treatment is key in 
producing positive treatment outcomes [63]. While the 
present study did not find support for the use of pre-
release buprenorphine to reduce HIV-risk behaviors, 
the parent study found that participants who initiated 
buprenorphine in prison had a higher mean number of 
days receiving buprenorphine treatment in the commu-
nity, suggesting that prison-initiated buprenorphine may 
improve treatment adherence in the community.
The present study has a few important limitations. 
First, response rates to certain items were quite low at the 
most distal follow-up periods (6 and 12  months) com-
pared to response rates at baseline and follow-ups closer 
to release and the overall rate of missing responses was 
high (54%). While multilevel modelling is equipped to 
handle missing data, if data are not missing completely at 
random [e.g., there is some systematic factor(s) account-
ing for missingness that is not included in the model], 
then information is lost in the analysis, potentially biasing 
parameter estimates. Second, an assumption of hierarchi-
cal linear models is a consistent effect of predictors over 
time, which may not be the case in reality when exam-
ining treatment effects that might be most potent in the 
time immediately after release. There is also an assump-
tion of linear change over time when using such models. 
While model comparisons showed that quadratic and 
cubic functions did not appear to fit the data better than 
a linear one, changes in instances of a particular behavior 
may be asymptotic in reality as they have floors (e.g. 
counts of behaviors cannot be negative) and ceilings that 
cannot be exceeded due to real world constraints. Third, 
self-reported data on HIV risk is subject to potential bias 
although such bias would likely be present across both 
conditions. Finally, recall of these behaviors, particularly 
for the 30 days prior to index incarceration, is subject to 
potential inaccuracy, which again would likely be equally 
present across both conditions.
More research is needed on the intersection of prison-
initiated pharmacotherapy and HIV treatment. At least 
one study [64] has found a positive association between 
24-week retention in buprenorphine treatment and 
maximal viral suppression (which is associated with 
improved HIV treatment outcomes). However, this 
study was quasi-experimental, as participants in a RCT 
of directly administered antiretroviral therapy for pris-
oners who met the DSM-IV criteria for opioid depend-
ence were offered buprenorphine pharmacotherapy while 
incarcerated and assessed post-release. Further research 
is needed to explore the relationship between prison-
based OAT and HIV treatment outcomes such as viral 
suppression and medication adherence.
Conclusions
Prison-initiated pharmacotherapy and continuing care 
in the community is still a promising intervention for 
improving treatment engagement in the community 
post-release, however, its merits as an intervention to 
reduce HIV-risk behaviors have not yet been demon-
strated. The wealth of research on the nexus of substance 
use and HIV risk suggests that reductions in substance 
use appear to be an important precursor to subsequent 
reductions in HIV-risk behavior. Therefore, future efforts 
to reduce HIV-risk behaviors among people with sub-
stance use disorders should focus on implementing the 
‘gold standard’ of evidence-based treatment, medication-
assisted treatment, and focus on effectively engaging 
patients in that treatment.
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